You just read:

Health Canada Approves TECENTRIQ™ (atezolizumab) for Patients with Locally Advanced and Metastatic Bladder Cancer

News provided by

Hoffmann-La Roche Limited (Roche Canada)

Apr 18, 2017, 08:00 ET